3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Unknown
3
Sponsor Class
INDUSTRY
6
OTHER
3
Study Type
Interventional
2
Observational
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Conditions
Study of Risk Factors for IPMNs Degeneration at the Nancy CHRU
1
Multiple Myeloma
1
Leukemia, Myeloid
1
Interventions
Cisplatin
352
Oxaliplatin
262
Capecitabine
258
Radiotherapy
240
Gemcitabine
223
Docetaxel
223
Carboplatin
223
Drug Therapy
219
Cyclophosphamide
219
Paclitaxel
205
apatinib
201
Bevacizumab
196
camrelizumab
190
Fluorouracil
188
sintilimab
133
Irinotecan
125
Blood Specimen Collection
125
Dexamethasone
123
Etoposide
119
Radiosurgery
118
toripalimab
117
Surgical Procedures, Operative
115
pembrolizumab
112
Pemetrexed
108
anlotinib
105
S 1 (combination)
105
Leucovorin
102
Surveys and Questionnaires
101
Nivolumab
98
tislelizumab
96
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Unknown
×
OTHER
×
Sensitivity and Specificity
×
Clear all
NCT04901364
2021-05-25
IPMN
Central Hospital, Nancy, France
Unknown
57 enrolled
NCT01864902
2016-01-28
CART33
Chinese PLA General Hospital
Phase 1/2
Unknown
10 enrolled
NCT01886976
2016-01-28
CART-138
Chinese PLA General Hospital
Phase 1/2
Unknown
10 enrolled